[
    [
        {
            "time": "",
            "original_text": "至于最近如火如荼的新冠疫苗方面，瑞科生物虽有所布局，但可惜介入时机点太慢，问市时间窗口并不明朗。",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "瑞科生物",
                    "布局",
                    "介入时机",
                    "问市时间"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "至于最近如火如荼的新冠疫苗方面，瑞科生物虽有所布局，但可惜介入时机点太慢，问市时间窗口并不明朗。",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "弘康人寿增资屡受挫 湖北首富终出局",
            "features": {
                "keywords": [
                    "弘康人寿",
                    "增资",
                    "屡受挫",
                    "湖北首富",
                    "出局"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "保险"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "弘康人寿增资屡受挫 湖北首富终出局",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报:政策负面预期趋稳,支付结构调整倒逼转型",
            "features": {
                "keywords": [
                    "医药行业",
                    "政策",
                    "负面预期",
                    "支付结构调整",
                    "转型"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报:政策负面预期趋稳,支付结构调整倒逼转型",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "2019年1月医药行业投资策略:“轻药重医”为正道,首推医疗器械板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "轻药重医",
                    "医疗器械板块"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2019年1月医药行业投资策略:'轻药重医'为正道,首推医疗器械板块",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "医药行业周观点:2019推荐配置具备消费属性的医药标的,持续推荐长春高新、我武生物等标的",
            "features": {
                "keywords": [
                    "医药行业",
                    "消费属性",
                    "长春高新",
                    "我武生物"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周观点:2019推荐配置具备消费属性的医药标的,持续推荐长春高新、我武生物等标的",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]